StockNews.AISignal intelligence
Vanda Pharmaceuticals Inc. · NASDAQ · Healthcare
Browse public VNDA signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Vanda Pharmaceuticals reported that its Phase III VP-VQW-765-3201 trial for social anxiety disorder did not meet the primary endpoint, and the program is on hold pending full data analysis. The failure undermines the asset’s prospects and could pressure VNDA’s near-term valuation, while management evaluates the pipeline and potential strategic options, including licensing or divestiture.
View signal analysisVanda Pharmaceuticals (VNDA) experienced a premarket surge after the FDA approved Bysanti, an oral treatment for bipolar I disorder and schizophrenia. With another drug under FDA review for a rare skin disease, VNDA's market outlook appears increasingly favorable, potentially attracting investor interest.
View signal analysisVanda Pharmaceuticals' shares have surged in premarket trading after the FDA approved Bysanti, a novel treatment for bipolar I disorder and schizophrenia. This approval is anticipated to bolster VNDA’s market presence and revenue prospects significantly.
View signal analysisVanda Pharmaceuticals has received FDA approval for a new drug aimed at treating two serious mental health conditions. This regulatory milestone is expected to enhance VNDA’s market share and potential revenues in a growing healthcare market.
View signal analysisVanda's new drug for motion-induced vomiting has been approved by U.S. regulators. This is the first approval for such treatment in over 40 years.
View signal analysisVanda reported positive topline tradipitant results preventing Wegovy-induced vomiting. Trial (n=116) showed vomiting reduced 58.6%→29.3% (≈50% relative reduction). Secondary endpoint also improved; no new safety signals observed. Vanda plans Phase 3 program targeting H1 2026; shares jumped ~16% on news. This addresses GLP-1 discontinuation drivers in a >$50B year-to-date GLP-1 market.
View signal analysis